Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.3953
Abstract: Prognosis of recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) remains poor. The addition of cetuximab, to platinum and fluorouracil chemotherapy (EXTREME regimen) has been shown to improve patients’ outcomes in first‐line… read more here.
Keywords: neck squamous; recurrent metastatic; metastatic head; cell carcinoma ... See more keywords
Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4722
Abstract: Anti‐PD1 checkpoint inhibitors (ICI) represent an established standard‐of‐care for patients with recurrent/metastatic head and neck squamous cell carcinoma (RMHNSCC). Landmark studies excluded patients with ECOG performance status (PS) ≥2; the benefit of ICI in this… read more here.
Keywords: head neck; metastatic head; checkpoint inhibitors; performance status ... See more keywords
Somatic mutations in tumor and plasma of locoregional recurrent and/or metastatic head and neck cancer using a next‐generation sequencing panel: A preliminary study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5436
Abstract: We explore the utility of TruSight Tumor 170 panel (TST170) for detecting somatic mutations in tumor and cfDNA from locoregional recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). read more here.
Keywords: locoregional recurrent; head neck; metastatic head; mutations tumor ... See more keywords
The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patients
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5522
Abstract: Response rates of immune checkpoint inhibitor (ICI) therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) are low. read more here.
Keywords: metastatic head; recurrent metastatic; head neck; immune checkpoint ... See more keywords
Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review.
Sign Up to like & getrecommendations! Published in 2019 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2019.05.002
Abstract: Recurrent or metastatic head and neck squamous-cell carcinomas (R/M HNSCC) are a group of cancers with a very poor prognosis. Many clinical trials testing novel target therapies in this setting are currently ongoing. We performed… read more here.
Keywords: systematic review; metastatic head; recurrent metastatic; target therapies ... See more keywords
Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis.
Sign Up to like & getrecommendations! Published in 2020 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2020.102984
Abstract: BACKGROUND The most effective regimen is unclear for patients with recurrent or metastatic head and neck squamous cell carcinomas (R/M HNSCC). We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) investigating only… read more here.
Keywords: neck squamous; recurrent metastatic; metastatic head; systematic review ... See more keywords
Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆.
Sign Up to like & getrecommendations! Published in 2017 at "Oral oncology"
DOI: 10.1016/j.oraloncology.2017.09.017
Abstract: OBJECTIVE Nivolumab is the first drug to demonstrate a survival benefit for platinum-refractory recurrent or metastatic head and neck cancer. We performed a cost-utility analysis to assess the economic value of nivolumab as compared to… read more here.
Keywords: recurrent metastatic; metastatic head; cost; cost effectiveness ... See more keywords
Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-82448-1
Abstract: Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker for clinical outcomes in various types of cancer, including recurrent or metastatic head and neck cancer (R/M HNSCC) treated with nivolumab,… read more here.
Keywords: recurrent metastatic; metastatic head; reactive protein; protein albumin ... See more keywords
Retreatment with nivolumab for patients with recurrent and/or metastatic head and neck cancer
Sign Up to like & getrecommendations! Published in 2022 at "Acta Oto-Laryngologica"
DOI: 10.1080/00016489.2022.2033317
Abstract: Abstract Background After treatment with an immune checkpoint inhibitor (ICI) is discontinued, retreatment with an ICI is a potential sequential treatment, but the clinical efficacy/safety data for this treatment of recurrent and/or metastatic head and… read more here.
Keywords: retreatment; metastatic head; niv cohort; treatment ... See more keywords
Locoregional treatment of primary tumor in synchronous metastatic head and neck squamous cell carcinomas.
Sign Up to like & getrecommendations! Published in 2023 at "Acta oncologica"
DOI: 10.1080/0284186x.2023.2209266
Abstract: Abstract Purpose Patients with synchronous metastatic head and neck squamous cell carcinomas (mHNSCC) are at risk of locoregional progression associated with significant morbidity and mortality. The aim of this study is to assess whether the… read more here.
Keywords: locoregional treatment; synchronous metastatic; systemic therapy; metastatic head ... See more keywords
Durable complete remission with local therapies after neoadjuvant and adjuvant nivolumab in recurrent/metastatic head and neck cancer
Sign Up to like & getrecommendations! Published in 2022 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000001422
Abstract: Up to 10–15% of patients with first-line recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) present with platinum-refractory disease. The anti-PD1 nivolumab is the first therapeutic option in this setting achieving a 19.2% objective… read more here.
Keywords: durable complete; head neck; metastatic head; disease ... See more keywords